MWN-103

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameMWN-103
Drug Alias NameMWN103MWN-103
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsFibroblast growth factor 21 agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide ReceptorFibroblast growth factor 21
Therapy Area/IndicationsDiabetes Mellitus, Type 2Sleep Apnea, ObstructiveMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Minwei Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Minwei Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Sleep Apnea, ObstructiveMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A